A review of a large clinical database revealed that approximately 40% of patients with neovascular age-related macular degeneration (nAMD) stopped VEGF therapy within the first year, increasing to a majority by the end of the second year. Visual acuity declined with decreasing injection frequency. Delayed treatment initiation was associated with poorer outcomes. Non-persistence in VEGF treatment was linked to worse fibrosis and atrophy.
A separate study analyzing the Vestrum Health Retina Database of 201,768 eyes found that 38.9% of patients became non-persistent within 12 months, with a corresponding decrease in the number of intravitreal injections. A trend analysis showed a surge in bevacizumab use, alongside increased use of biosimilars, and variation in therapy choices by indication. Switching to bevacizumab after 2023 was associated with a decline in visual acuity, as reported in a poster presentation.
The analysis of the Vestrum database in 2025 indicated that bevacizumab and faricimab accounted for nearly half of all nAMD injections, while biosimilar aflibercept-ayyh was the most common biosimilar used. The increased use of bevacizumab was attributed to patient challenges related to co-pay support.”} p>